Insulin efsitora alfa  (Synonyms: LY-3209590)

Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes^[1].

Insulin efsitora alfa (0.01-100 nM) stimulates human insulin receptor isoform A (hIR-A) and human insulin receptor isoform B (hIR-B) phosphorylation in HEK293 cells with EC₅₀ values of 4241 nM and 391 nM, respectively^[2].
Insulin efsitora alfa (20 µM; 30 min) significantly promotes the dephosphorylation of hIR-A and hIR-B^[2].
Insulin efsitora alfa stimulates the lipogenesis of 3T3-L1 adipocytes and the proliferation of SAOS-2 and H4IIE cells with EC₅₀ values of 19 nM, 134 nM and 20 nM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Insulin efsitora alfa (3, 10 and 30 nmol/kg; s.c.; single dose) significantly reduces blood glucose in diabetes rats treated with Streptozotocin (HY-13753)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

64.1 kDa

2131038-11-2

Liquid

Colorless to light yellow

[Insulin efsitora alfa]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  INS (insulin, IDDM1, IDDM2, "insulin-dependent diabetes mellitus 2")-IGHG2 Fc (Fragment constant)

• [1]. Heise T, et al. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes Obes Metab. 2023 Apr;25(4):1080-1090.  [Content Brief]

  [2]. Moyers JS, et al. Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein. J Pharmacol Exp Ther. 2022 Sep;382(3):346-355.  [Content Brief]